2011
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecologic Oncology 2011, 122: 171-177. PMID: 21453957, PMCID: PMC3104081, DOI: 10.1016/j.ygyno.2011.03.002.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCell Adhesion MoleculesCell Line, TumorDrug Resistance, NeoplasmFemaleFlow CytometryHumansImmunoglobulin GImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedMolecular Targeted TherapyOvarian NeoplasmsRNA, MessengerConceptsAntibody-dependent cellular cytotoxicityOvarian cancer cell linesTrop-2 expressionAnti-Trop-2 antibodyChemotherapy-resistant ovarian cancerPrimary ovarian cancer cell linesCancer cell linesOvarian carcinoma cell linesInterleukin-2Cell surface markersCarcinoma cell linesOvarian cancerCell linesTrop-2Therapeutic agentsChemotherapy-resistant diseaseNovel therapeutic agentsEffect of serumOvarian diseaseControl antibodyHRS7Real-time PCRCellular cytotoxicityCarcinoma specimensRelease assays
2010
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Clear CellAnimalsCarcinoma, PapillaryCarcinoma, Squamous CellChlorocebus aethiopsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleFibroblastsFlow CytometryHumansMembrane ProteinsMiceMice, SCIDOvarian NeoplasmsPeptide FragmentsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSpheroids, CellularTissue DistributionTransplantation, HeterologousTumor Cells, CulturedUterine Cervical NeoplasmsVero CellsConceptsChemotherapy-resistant ovarian cancerClostridium perfringens enterotoxinOvarian cancerOvarian carcinoma cell linesClaudin-3Carcinoma cell linesNovel tumor-homing peptideCarboxy-terminal fragmentTumor cellsResistant ovarian cancer cell linesCell linesNew diagnostic tracersCPE peptideOvarian cancer cell linesResistant ovarian cancer cellsResistant ovarian carcinomaHuman ovarian cancerRelevant animal modelsOvarian tumor cellsOvarian cancer cellsChemotherapy-resistant ovarian cancer cellsHuman epithelial tumorsTime-dependent internalizationCancer cell linesBio-distribution studies
2009
Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBlotting, WesternCarcinoma, PapillaryCell Adhesion MoleculesChemotherapy, AdjuvantCystadenocarcinoma, SerousDrug Resistance, NeoplasmEndometrial NeoplasmsEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansImmunoenzyme TechniquesMiddle AgedNeoplasm Recurrence, LocalOrganoplatinum CompoundsOvarian NeoplasmsOvaryPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateTreatment OutcomeTumor Cells, CulturedConceptsRecurrent epithelial ovarian carcinomaEpithelial ovarian carcinomaNormal ovarian tissuesOvarian carcinoma cell linesOvarian carcinomaEpithelial cell adhesion moleculeEp-CAMCarcinoma cell linesCell adhesion moleculeOvarian tissueChemotherapy-resistant epithelial ovarian cancerFlow cytometryCell linesAdhesion moleculesEp-CAM overexpressionStandard treatment modalityCell adhesion molecule expressionOvarian carcinoma patientsEpithelial ovarian cancerPrimary ovarian carcinomasAdhesion molecule expressionSurface expressionAntibody-mediated therapyHuman monoclonal antibodyEpithelial cell adhesion molecule (EpCAM) expression
1999
Secretion of vascular endothelial growth factor in ovarian cancer.
Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. European Journal Of Gynaecological Oncology 1999, 20: 177-81. PMID: 10410879.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorOvarian cancer patientsCancer patientsOvarian carcinoma cell linesEnzyme-linked immunosorbent assayEndothelial growth factorOvarian cancerCarcinoma cell linesAscitic fluidFluid accumulationLow vascular endothelial growth factorVEGF secretionGrowth factorTumor-Induced ImmunosuppressionVascular endothelial cell functionDefective immune functionHigh-grade malignancyLow-grade tumorsHuman ovarian carcinoma cell linesAnti-angiogenic treatmentNovel therapeutic approachesPeritoneal fluid accumulationAction of VEGFCell linesAscitic fluid accumulation
1996
Differential Effects of High-Dose Gamma Irradiation on the Production of Transforming Growth Factor-Beta in Fresh and Established Human Ovarian Cancer
Santin A, Hiserodt J, DiSaia P, Pecorelli S, Granger G. Differential Effects of High-Dose Gamma Irradiation on the Production of Transforming Growth Factor-Beta in Fresh and Established Human Ovarian Cancer. Gynecologic Oncology 1996, 61: 403-408. PMID: 8641623, DOI: 10.1006/gyno.1996.0164.Peer-Reviewed Original ResearchConceptsOvarian carcinoma cell linesCarcinoma cell linesOvarian tumorsFresh tumorsCell linesHigh dosesImmunoinhibitory cytokinesTumor cellsFresh ovarian tumorsTGF-beta secretionTGF-beta productionCytokines TNF-alphaFresh tumor cellsWeak immunological responseFresh tumor samplesHuman ovarian cancerHuman ovarian carcinoma cell linesTNF-alphaOvarian cancerImmunological responseIFN-gammaCytokinesTumorsTumor samplesContinuous cell linesEffects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer
Santin A, Hiserodt J, Fruehauf J, DiSaia P, Pecorelli S, Granger G. Effects of Irradiation on the Expression of Surface Antigens in Human Ovarian Cancer. Gynecologic Oncology 1996, 60: 468-474. PMID: 8774659, DOI: 10.1006/gyno.1996.0075.Peer-Reviewed Original ResearchConceptsMHC class ISurface antigenHER2-neuHigh dosesClass IITumor cellsCell linesClass IICAM-1 antigenHuman ovarian cancerHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCA 125Carcinoma cell linesOvarian cancerICAM-1Radiation therapyIrradiation-induced upregulationImmune recognitionTumor tissueAntigenDosesCellsExposureExpressionDevelopment and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules
Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.Peer-Reviewed Original ResearchConceptsIL-2Interleukin-2Ovarian carcinoma cellsOvarian cancerAllogeneic peripheral blood lymphocytesAdvanced epithelial ovarian cancerBALB/c nude miceChromium-51 release assaysMajor histocompatibility complex class IAdvance ovarian cancerCarcinoma cellsHistocompatibility complex class IEpithelial ovarian cancerMajor histocompatibility complex moleculesPeripheral blood lymphocytesHuman ovarian carcinoma cell linesHuman ovarian carcinoma cellsOvarian carcinoma cell linesComplex class ICytokine interleukin-2Long-term cytotoxicHistocompatibility complex moleculesMonths of studyUCI-107Tumor vaccines
1995
Development and in vitro characterization of a GM‐CSF secreting human ovarian carcinoma tumor vaccine
Santin AD, Ioli GR, Hiserodt JC, Rose GS, Graf MR, Lander JK, Disaia PJ, Pecorelli S, Granger GA. Development and in vitro characterization of a GM‐CSF secreting human ovarian carcinoma tumor vaccine. International Journal Of Gynecological Cancer 1995, 5: 401-410. PMID: 11578512, DOI: 10.1046/j.1525-1438.1995.05060401.x.Peer-Reviewed Original ResearchDevelopment and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line
Santin A, Ioli G, Hiserodt J, Rose G, Graf M, Tocco L, Lander J, Eck L, Burger R, DiSaia P, Pecorelli S, Granger G. Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line. Gynecologic Oncology 1995, 58: 230-239. PMID: 7622110, DOI: 10.1006/gyno.1995.1216.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntigens, SurfaceCell DivisionCell SurvivalClone CellsCystadenocarcinoma, PapillaryDNA, NeoplasmDNA, ViralFemaleGenetic VectorsHistocompatibility Antigens Class IHumansIntercellular Adhesion Molecule-1Interleukin-4KineticsOvarian NeoplasmsPlasmidsRetroviridaeTransduction, GeneticTumor Cells, CulturedVaccinesConceptsHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCarcinoma cell linesInterleukin-4UCI-107Detectable MHC class IICell linesAdvanced ovarian cancerIL-4 secretionMHC class IICytokine interleukin-4IL-4 receptorMHC class ILXSN retroviral vectorOvarian carcinoma cellsIL-4 geneMonths of studyCA 125Ovarian cancerICAM-1Parental cell lineDay 8Vector control cellsClass IIUCI 101